메뉴 건너뛰기




Volumn 11, Issue 4, 2016, Pages 417-423

Persistent HIV-1 replication during antiretroviral therapy

Author keywords

abnormal levels of immune activation and inflammation; cell to cell infection; HIV residual replication during ART; limited drug penetration within tissues; presence of immune sanctuaries

Indexed keywords

ANTIRETROVIRUS AGENT; RALTEGRAVIR;

EID: 84963526778     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000287     Document Type: Review
Times cited : (132)

References (70)
  • 1
    • 0033577801 scopus 로고    scopus 로고
    • Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA
    • Hockett RD, Kilby JM, et al. Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. J Exp Med 1999; 189:1545-1554.
    • (1999) J Exp Med , vol.189 , pp. 1545-1554
    • Hockett, R.D.1    Kilby, J.M.2
  • 2
    • 58149382617 scopus 로고    scopus 로고
    • Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy
    • Hatano H, Delwart EL, et al. Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol 2009; 83:329-335.
    • (2009) J Virol , vol.83 , pp. 329-335
    • Hatano, H.1    Delwart, E.L.2
  • 3
    • 78649431227 scopus 로고    scopus 로고
    • HIV-1 continues to replicate and evolve in patients with natural control of HIV infection
    • Mens H, Kearney M, et al. HIV-1 continues to replicate and evolve in patients with natural control of HIV infection. J Virol 2010; 84:12971-12981.
    • (2010) J Virol , vol.84 , pp. 12971-12981
    • Mens, H.1    Kearney, M.2
  • 4
    • 84885407337 scopus 로고    scopus 로고
    • Effect of antiretroviral therapy on HIV reservoirs in elite controllers
    • Chun TW, Shawn Justement J, et al. Effect of antiretroviral therapy on HIV reservoirs in elite controllers. J Infect Dis 2013; 208:1443-1447.
    • (2013) J Infect Dis , vol.208 , pp. 1443-1447
    • Chun, T.W.1    Shawn Justement, J.2
  • 5
    • 84887290531 scopus 로고    scopus 로고
    • Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers
    • Hatano H, Yukl SA, et al. Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. PLoS Pathog 2013; 9:e1003691.
    • (2013) PLoS Pathog , vol.9
    • Hatano, H.1    Yukl, S.A.2
  • 6
    • 34247584237 scopus 로고    scopus 로고
    • ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia
    • Maldarelli F, Palmer S, et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 2007; 3:e46.
    • (2007) PLoS Pathog , vol.3 , pp. e46
    • Maldarelli, F.1    Palmer, S.2
  • 7
    • 41649083599 scopus 로고    scopus 로고
    • Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy
    • Palmer S, Maldarelli F, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 2008; 105:3879-3884.
    • (2008) Proc Natl Acad Sci U S A , vol.105 , pp. 3879-3884
    • Palmer, S.1    Maldarelli, F.2
  • 8
    • 55949083820 scopus 로고    scopus 로고
    • HIV rebounds from latently infected cells, rather than from continuing low-level replication
    • Joos B, Fischer M, et al. HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A 2008; 105:16725-16730.
    • (2008) Proc Natl Acad Sci U S A , vol.105 , pp. 16725-16730
    • Joos, B.1    Fischer, M.2
  • 9
    • 84860908013 scopus 로고    scopus 로고
    • Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection
    • Evering TH, Mehandru S, et al. Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. PLoS Pathog 2012; 8:e1002506.
    • (2012) PLoS Pathog , vol.8
    • Evering, T.H.1    Mehandru, S.2
  • 10
    • 84890847660 scopus 로고    scopus 로고
    • The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time
    • Josefsson L, von Stockenstrom S, et al. The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. Proc Natl Acad Sci U S A 2013; 110:E4987-E4996.
    • (2013) Proc Natl Acad Sci U S A , vol.110 , pp. E4987-E4996
    • Josefsson, L.1    Von Stockenstrom, S.2
  • 11
    • 84897437605 scopus 로고    scopus 로고
    • Lack of detectable HIV-1 molecular evolution during suppressive antiretroviral therapy
    • Kearney MF, Spindler J, et al. Lack of detectable HIV-1 molecular evolution during suppressive antiretroviral therapy. PLoS Pathog 2014; 10:e1004010
    • (2014) PLoS Pathog , vol.10
    • Kearney, M.F.1    Spindler, J.2
  • 12
    • 84958088008 scopus 로고    scopus 로고
    • Origin of rebound plasma HIV includes cells with identical proviruses that are transcriptionally active before stopping of antiretroviral therapy
    • Kearney MF, Wiegand A, et al. Origin of rebound plasma HIV includes cells with identical proviruses that are transcriptionally active before stopping of antiretroviral therapy. J Virol 2015; 90:1369-1376
    • (2015) J Virol , vol.90 , pp. 1369-1376
    • Kearney, M.F.1    Wiegand, A.2
  • 13
    • 84957558724 scopus 로고    scopus 로고
    • Persistent HIV-1 replication maintains the tissue reservoir during therapy
    • Lorenzo-Redondo R, Fryer HR, et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature 2016; 530:51-56
    • (2016) Nature , vol.530 , pp. 51-56
    • Lorenzo-Redondo, R.1    Fryer, H.R.2
  • 14
    • 67249121143 scopus 로고    scopus 로고
    • Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy
    • Dinoso JB, Kim SY, et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A 2009; 106:9403-9408.
    • (2009) Proc Natl Acad Sci U S A , vol.106 , pp. 9403-9408
    • Dinoso, J.B.1    Kim, S.Y.2
  • 15
    • 77749277080 scopus 로고    scopus 로고
    • Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy
    • McMahon D, Jones J, et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 2010; 50:912-919.
    • (2010) Clin Infect Dis , vol.50 , pp. 912-919
    • McMahon, D.1    Jones, J.2
  • 16
    • 79953000877 scopus 로고    scopus 로고
    • A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response
    • Hatano H, Hayes TL, et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis 2011; 203:960-968.
    • (2011) J Infect Dis , vol.203 , pp. 960-968
    • Hatano, H.1    Hayes, T.L.2
  • 17
    • 80054739868 scopus 로고    scopus 로고
    • Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: A randomized controlled trial
    • Byakwaga H, Kelly M, et al. Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial. J Infect Dis 2011; 204:1532-1540.
    • (2011) J Infect Dis , vol.204 , pp. 1532-1540
    • Byakwaga, H.1    Kelly, M.2
  • 18
    • 84860345691 scopus 로고    scopus 로고
    • Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: A randomized 48-week study
    • Llibre JM, Buzó n MJ, et al. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antivir Ther 2012; 17:355-364.
    • (2012) Antivir Ther , vol.17 , pp. 355-364
    • Llibre, J.M.1    Buzó, N.M.J.2
  • 19
    • 84859752894 scopus 로고    scopus 로고
    • No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy
    • Gandhi RT, Coombs RW, et al. No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2012; 59:229-235.
    • (2012) J Acquir Immune Defic Syndr , vol.59 , pp. 229-235
    • Gandhi, R.T.1    Coombs, R.W.2
  • 20
    • 84866707088 scopus 로고    scopus 로고
    • The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients
    • Vallejo A, Gutierrez C, et al. The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients. AIDS 2012; 26:1885-1894.
    • (2012) AIDS , vol.26 , pp. 26-1885
    • Vallejo, A.1    Gutierrez, C.2
  • 21
    • 84880421532 scopus 로고    scopus 로고
    • The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: A randomized trial
    • Hunt PW, Shulman NS, et al. The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood 2013; 121:4635-4646.
    • (2013) Blood , vol.121 , pp. 4635-4646
    • Hunt, P.W.1    Shulman, N.S.2
  • 22
    • 77950537810 scopus 로고    scopus 로고
    • HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects
    • Buzó n MJ, Massanella M, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010; 16:460-465.
    • (2010) Nat Med , vol.16 , pp. 460-465
    • Buzó, N.M.J.1    Massanella, M.2
  • 23
    • 84885411247 scopus 로고    scopus 로고
    • Increasein2-longterminal repeatcircles anddecrease in D-dimer after raltegravir intensification in patients with treated HIV infection: A randomized, placebo-controlled trial
    • Hatano H, Strain MC, et al. Increasein2-longterminal repeatcircles anddecrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis 2013; 208:1436-1442.
    • (2013) J Infect Dis , vol.208 , pp. 1436-1442
    • Hatano, H.1    Strain, M.C.2
  • 24
    • 84878666650 scopus 로고    scopus 로고
    • Modelling HIV-1 2-LTR dynamics following raltegravir intensification
    • Luo R, Cardozo EF, et al. Modelling HIV-1 2-LTR dynamics following raltegravir intensification. J R Soc Interface 2013; 10:20130186.
    • (2013) J R Soc Interface , vol.10
    • Luo, R.1    Cardozo, E.F.2
  • 25
    • 84894046809 scopus 로고    scopus 로고
    • Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection
    • Puertas MC, Massanella M, et al. Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection. AIDS 2014; 28:325-334.
    • (2014) AIDS , vol.28 , pp. 325-334
    • Puertas, M.C.1    Massanella, M.2
  • 26
    • 84879774999 scopus 로고    scopus 로고
    • Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensification
    • Massanella M, Esteve A, et al. Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensification. J Acquir Immune Defic Syndr 2013; 63:152-160.
    • (2013) J Acquir Immune Defic Syndr , vol.63 , pp. 152-160
    • Massanella, M.1    Esteve, A.2
  • 27
    • 80055078962 scopus 로고    scopus 로고
    • Deep molecular characterization of HIV-1 dynamics under suppressive HAART
    • Buzó n MJ, Codoñer FM, et al. Deep molecular characterization of HIV-1 dynamics under suppressive HAART. PLoS Pathog 2011; 7:e1002314.
    • (2011) PLoS Pathog , vol.7
    • Buzó, N.M.J.1    Codoñer, F.M.2
  • 28
    • 84891933529 scopus 로고    scopus 로고
    • Spatial modeling of HIV cryptic viremia and 2-LTR formation during raltegravir intensification
    • Cardozo EF, Luo R, Piovoso MJ, Zurakowski R. Spatial modeling of HIV cryptic viremia and 2-LTR formation during raltegravir intensification. J Theor Biol 2014; 345:61-69.
    • (2014) J Theor Biol , vol.345 , pp. 61-69
    • Cardozo, E.F.1    Luo, R.2    Piovoso, M.J.3    Zurakowski, R.4
  • 30
    • 84957845066 scopus 로고    scopus 로고
    • The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption
    • Li JZ, Etemad B, et al. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS 2016; 30:343-353
    • (2016) AIDS , vol.30 , pp. 343-353
    • Li, J.Z.1    Etemad, B.2
  • 31
    • 78549245806 scopus 로고    scopus 로고
    • Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy
    • Yukl SA, Shergill AK, et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS 2010; 24:2451-2460.
    • (2010) AIDS , vol.24 , pp. 2451-2460
    • Yukl, S.A.1    Shergill, A.K.2
  • 32
    • 77953791222 scopus 로고    scopus 로고
    • Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus
    • O'Connell KA, Brennan TP, et al. Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. J Virol 2010; 84:7018-7028.
    • (2010) J Virol , vol.84 , pp. 7018-7028
    • O'Connell, K.A.1    Brennan, T.P.2
  • 33
    • 80052395837 scopus 로고    scopus 로고
    • Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy
    • Sigal A, Kim JT, et al. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 2011; 477:95-98.
    • (2011) Nature , vol.477 , pp. 95-98
    • Sigal, A.1    Kim, J.T.2
  • 34
    • 70349296826 scopus 로고    scopus 로고
    • Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiretroviral therapy
    • Shiu C, Cunningham CK, et al. Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiretroviral therapy. J Virol 2009; 83:9731-9742.
    • (2009) J Virol , vol.83 , pp. 9731-9742
    • Shiu, C.1    Cunningham, C.K.2
  • 35
    • 84904485194 scopus 로고    scopus 로고
    • Evolution of HIV-1 quasispecies and coreceptor use in cell reservoirs of patients on suppressive antiretroviral therapy
    • Raymond S, Saliou A, et al. Evolution of HIV-1 quasispecies and coreceptor use in cell reservoirs of patients on suppressive antiretroviral therapy. J Antimicrob Chemother 2014; 69:2527-2530.
    • (2014) J Antimicrob Chemother , vol.69 , pp. 2527-2530
    • Raymond, S.1    Saliou, A.2
  • 36
    • 84904891621 scopus 로고    scopus 로고
    • Stochastic population switch may explain the latent reservoir stability and intermittent viral blips in HIV patients on suppressive therapy
    • Wang S, Rong L. Stochastic population switch may explain the latent reservoir stability and intermittent viral blips in HIV patients on suppressive therapy. J Theor Biol 2014; 360:137-148
    • (2014) J Theor Biol , vol.360 , pp. 137-148
    • Wang, S.1    Rong, L.2
  • 37
    • 84956780091 scopus 로고    scopus 로고
    • Residual viremia in treated HIV+ individuals
    • Conway JM, Perelson AS. Residual viremia in treated HIV+ individuals. PLoS Comput Biol 2016; 12:e1004677
    • (2016) PLoS Comput Biol , vol.12
    • Conway, J.M.1    Perelson, A.S.2
  • 38
    • 46049096485 scopus 로고    scopus 로고
    • Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs
    • Shen L, Peterson S, et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med 2008; 14:762-766.
    • (2008) Nat Med , vol.14 , pp. 762-766
    • Shen, L.1    Peterson, S.2
  • 39
    • 79960373686 scopus 로고    scopus 로고
    • A critical subset model provides a conceptual basis for the high antiviral activity of major HIV drugs
    • Shen L, Rabi SA, et al. A critical subset model provides a conceptual basis for the high antiviral activity of major HIV drugs. Sci Transl Med 2011; 3:91ra63.
    • (2011) Sci Transl Med , vol.3 , pp. 91ra63
    • Shen, L.1    Rabi, S.A.2
  • 40
    • 84857955750 scopus 로고    scopus 로고
    • A quantitative basis for antiretroviral therapy for HIV-1 infection
    • Jilek BL, Zarr M, et al. A quantitative basis for antiretroviral therapy for HIV-1 infection. Nat Med 2012; 18:446-451.
    • (2012) Nat Med , vol.18 , pp. 446-451
    • Jilek, B.L.1    Zarr, M.2
  • 41
    • 84925536169 scopus 로고    scopus 로고
    • Cell-cell contact viral transfer contributes to HIV infection and persistence in astrocytes
    • Luo X, He JJ. Cell-cell contact viral transfer contributes to HIV infection and persistence in astrocytes. J Neurovirol 2015; 21:66-80
    • (2015) J Neurovirol , vol.21 , pp. 66-80
    • Luo, X.1    He, J.J.2
  • 42
    • 84941182496 scopus 로고    scopus 로고
    • Cell-to-cell transmission of HIV-1 is required to trigger pyroptotic death of lymphoid-tissue-derived CD4 T cells
    • Galloway NL, Doitsh G, et al. Cell-to-cell transmission of HIV-1 is required to trigger pyroptotic death of lymphoid-tissue-derived CD4 T cells. Cell Rep 2015; 12:1555-1563
    • (2015) Cell Rep , vol.12 , pp. 1555-1563
    • Galloway, N.L.1    Doitsh, G.2
  • 43
    • 84893830170 scopus 로고    scopus 로고
    • Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues
    • Fletcher CV, Staskus K, et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A 2014; 111:2307-2312
    • (2014) Proc Natl Acad Sci U S A , vol.111 , pp. 2307-2312
    • Fletcher, C.V.1    Staskus, K.2
  • 44
    • 83155177076 scopus 로고    scopus 로고
    • Penetration of tenofovir and emtricitabine in mucosal tissues: Implications for prevention of HIV-1 transmission
    • Patterson KB, Prince HA, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med 2011; 3:112re4.
    • (2011) Sci Transl Med , vol.3 , pp. 112re4
    • Patterson, K.B.1    Prince, H.A.2
  • 45
    • 84879084001 scopus 로고    scopus 로고
    • Differential penetration of raltegravir throughout gastrointestinal tissue: Implications for eradication and cure
    • Patterson KB, Prince HA, et al. Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure. AIDS 2013; 27:1413-1419.
    • (2013) AIDS , vol.27 , pp. 1413-1419
    • Patterson, K.B.1    Prince, H.A.2
  • 46
    • 0031011147 scopus 로고    scopus 로고
    • Germinal centre CD4+ T cells are an important site of HIV replication in vivo
    • Hufert FT, van Lunzen J, et al. Germinal centre CD4+ T cells are an important site of HIV replication in vivo. AIDS 1997; 11:849-857.
    • (1997) AIDS , vol.11 , pp. 849-857
    • Hufert, F.T.1    Van Lunzen, J.2
  • 47
    • 84874519282 scopus 로고    scopus 로고
    • Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production
    • Perreau M, Savoye AL, et al. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J Exp Med 2013; 210:143-156.
    • (2013) J Exp Med , vol.210 , pp. 143-156
    • Perreau, M.1    Savoye, A.L.2
  • 48
    • 84922611542 scopus 로고    scopus 로고
    • B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers
    • Fukazawa Y, Lum R, et al. B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers. Nat Med 2015; 21:132-139
    • (2015) Nat Med , vol.21 , pp. 132-139
    • Fukazawa, Y.1    Lum, R.2
  • 49
    • 34249800097 scopus 로고    scopus 로고
    • CTL fail to accumulate at sites of HIV-1 replication in lymphoid tissue
    • Connick E, Mattila T, et al. CTL fail to accumulate at sites of HIV-1 replication in lymphoid tissue. J Immunol 2007; 178:6975-6983.
    • (2007) J Immunol , vol.178 , pp. 6975-6983
    • Connick, E.1    Mattila, T.2
  • 50
    • 84912569301 scopus 로고    scopus 로고
    • Compartmentalization of simian immunodeficiency virus replication within secondary lymphoid tissues of rhesus macaques is linked to disease stage and inversely related to localization of virusspecific CTL
    • Connick E, Folkvord JM, et al. Compartmentalization of simian immunodeficiency virus replication within secondary lymphoid tissues of rhesus macaques is linked to disease stage and inversely related to localization of virusspecific CTL. J Immunol 2014; 193:5613-5625.
    • (2014) J Immunol , vol.193 , pp. 5613-5625
    • Connick, E.1    Folkvord, J.M.2
  • 51
    • 84939885264 scopus 로고    scopus 로고
    • Evidence for cFMS signaling in HIV production by brain macrophages and microglia
    • Gerngross L, Fischer T. Evidence for cFMS signaling in HIV production by brain macrophages and microglia. J Neurovirol 2015; 21:249-256.
    • (2015) J Neurovirol , vol.21 , pp. 249-256
    • Gerngross, L.1    Fischer, T.2
  • 52
    • 84908638742 scopus 로고    scopus 로고
    • Residual viremia is preceding viral blips and persistent low-level viremia in treated HIV-1 patients
    • Hofstra LM, Mudrikova T, et al. Residual viremia is preceding viral blips and persistent low-level viremia in treated HIV-1 patients. PLoS One 2014; 9:e110749.
    • (2014) PLoS One , vol.9
    • Hofstra, L.M.1    Mudrikova, T.2
  • 53
    • 77955001673 scopus 로고    scopus 로고
    • Recovery of replication-competent residual HIV-1 from plasma of a patient receiving prolonged, suppressive highly active antiretroviral therapy
    • Sahu GK, Sarria JC, Cloyd MW. Recovery of replication-competent residual HIV-1 from plasma of a patient receiving prolonged, suppressive highly active antiretroviral therapy. J Virol 2010; 84:8348-8352.
    • (2010) J Virol , vol.84 , pp. 8348-8352
    • Sahu, G.K.1    Sarria, J.C.2    Cloyd, M.W.3
  • 54
    • 71549143183 scopus 로고    scopus 로고
    • Microbial translocation is associated with residual viral replication in HAART-treated HIV+ subjects with <50 copies/ml HIV-1 RNA
    • Baroncelli S, Galluzzo CM, et al. Microbial translocation is associated with residual viral replication in HAART-treated HIV+ subjects with <50 copies/ml HIV-1 RNA. J Clin Virol 2009; 46:367-370.
    • (2009) J Clin Virol , vol.46 , pp. 367-370
    • Baroncelli, S.1    Galluzzo, C.M.2
  • 55
    • 68349139711 scopus 로고    scopus 로고
    • HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation
    • Chomont N, El-Far M, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15:893-900.
    • (2009) Nat Med , vol.15 , pp. 893-900
    • Chomont, N.1    El-Far, M.2
  • 56
    • 84878542117 scopus 로고    scopus 로고
    • Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells
    • Hatano H, Jain V, et al. Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. J Infect Dis 2013; 208:50-56.
    • (2013) J Infect Dis , vol.208 , pp. 50-56
    • Hatano, H.1    Jain, V.2
  • 57
    • 84879318140 scopus 로고    scopus 로고
    • Immune activation and HIV persistence: Implications for curative approaches to HIV infection
    • Klatt NR, Chomont N, Douek DC, Deeks SG. Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol Rev 2013; 254:326-342.
    • (2013) Immunol Rev , vol.254 , pp. 326-342
    • Klatt, N.R.1    Chomont, N.2    Douek, D.C.3    Deeks, S.G.4
  • 58
    • 84879302206 scopus 로고    scopus 로고
    • Interleukin-7 promotes HIV persistence during antiretroviral therapy
    • Vandergeeten C, Fromentin R, et al. Interleukin-7 promotes HIV persistence during antiretroviral therapy. Blood 2013; 121:4321-4329.
    • (2013) Blood , vol.121 , pp. 4321-4329
    • Vandergeeten, C.1    Fromentin, R.2
  • 59
    • 84894554674 scopus 로고    scopus 로고
    • HIV DNA subspecies persist in both activated and resting memory CD4+ T cells during antiretroviral therapy
    • Murray JM, Zaunders JJ, et al. HIV DNA subspecies persist in both activated and resting memory CD4+ T cells during antiretroviral therapy. J Virol 2014; 88:3516-3526.
    • (2014) J Virol , vol.88 , pp. 3516-3526
    • Murray, J.M.1    Zaunders, J.J.2
  • 60
    • 84904128252 scopus 로고    scopus 로고
    • Immunologic strategies for HIV-1 remission and eradication
    • Barouch DH, Deeks SG. Immunologic strategies for HIV-1 remission and eradication. Science 2014; 345:169-174.
    • (2014) Science , vol.345 , pp. 169-174
    • Barouch, D.H.1    Deeks, S.G.2
  • 61
    • 84878981012 scopus 로고    scopus 로고
    • Barriers to a cure for HIV: New ways to target and eradicate HIV-1 reservoirs
    • Katlama C, Deeks SG, et al. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet 2013; 381:2109-2117.
    • (2013) Lancet , vol.381 , pp. 2109-2117
    • Katlama, C.1    Deeks, S.G.2
  • 62
    • 84948807352 scopus 로고    scopus 로고
    • Interleukin-21 combined with ART reduces inflammation and viral reservoir in SIV-infected macaques
    • Micci L, Ryan ES, et al. Interleukin-21 combined with ART reduces inflammation and viral reservoir in SIV-infected macaques. J Clin Invest 2015; 125:4497-4513
    • (2015) J Clin Invest , vol.125 , pp. 4497-4513
    • Micci, L.1    Ryan, E.S.2
  • 63
    • 84943154337 scopus 로고    scopus 로고
    • Formulation and pharmacology of long-acting cabotegravir
    • Trezza C, Ford SL, et al. Formulation and pharmacology of long-acting cabotegravir. Curr Opin HIV AIDS 2015; 10:239-245.
    • (2015) Curr Opin HIV AIDS , vol.10 , pp. 239-245
    • Trezza, C.1    Ford, S.L.2
  • 64
    • 84871947792 scopus 로고    scopus 로고
    • Harnessing the therapeutic potential of host antiviral restriction factors that target HIV
    • Sloan RD, Wainberg MA. Harnessing the therapeutic potential of host antiviral restriction factors that target HIV. Expert Rev Anti Infect Ther 2013; 11:1-4.
    • (2013) Expert Rev Anti Infect Ther , vol.11 , pp. 1-4
    • Sloan, R.D.1    Wainberg, M.A.2
  • 65
    • 84887626950 scopus 로고    scopus 로고
    • Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys
    • Barouch DH, Whitney JB, et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 2013; 503:224-228.
    • (2013) Nature , vol.503 , pp. 224-228
    • Barouch, D.H.1    Whitney, J.B.2
  • 66
    • 84887627657 scopus 로고    scopus 로고
    • Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia
    • Shingai M, Nishimura Y, et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 2013; 503:277-280.
    • (2013) Nature , vol.503 , pp. 277-280
    • Shingai, M.1    Nishimura, Y.2
  • 67
    • 84937950533 scopus 로고    scopus 로고
    • Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys
    • Barouch DH, Alter G, et al. Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. Science 2015; 349:320-324.
    • (2015) Science , vol.349 , pp. 320-324
    • Barouch, D.H.1    Alter, G.2
  • 68
    • 84924375707 scopus 로고    scopus 로고
    • AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges
    • Gardner MR, Kattenhorn LM, et al. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature 2015; 519: 87-91.
    • (2015) Nature , vol.519 , pp. 87-91
    • Gardner, M.R.1    Kattenhorn, L.M.2
  • 69
    • 84928880432 scopus 로고    scopus 로고
    • Whole-body immunoPET reveals active SIV dynamics in viremic and antiretroviral therapy-treated macaques
    • Santangelo PJ, Rogers KA, et al. Whole-body immunoPET reveals active SIV dynamics in viremic and antiretroviral therapy-treated macaques. Nat Methods 2015; 12:427-432.
    • (2015) Nat Methods , vol.12 , pp. 427-432
    • Santangelo, P.J.1    Rogers, K.A.2
  • 70
    • 84899573008 scopus 로고    scopus 로고
    • HIV antibody characterization as a method to quantify reservoir size during curative interventions
    • Burbelo PD, Bayat A, et al. HIV antibody characterization as a method to quantify reservoir size during curative interventions. J Infect Dis 2014; 209:1613-1617.
    • (2014) J Infect Dis , vol.209 , pp. 1613-1617
    • Burbelo, P.D.1    Bayat, A.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.